Newron has been forced to delay the start of a pivotal trial of its schizophrenia candidate evenamide – tipped as a potential blockbuster – after an FDA query about safety data from animal studies. The Italian biopharma says the US regulator is co...
Original Article: Newron faces delay to would-be schizophrenia blockbuster